BioDelivery Sciences International Inc. (NASDAQ:BDSI) has been assigned a $6.00 price objective by Roth Capital in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s target price indicates a potential upside of 258.21% from the company’s current price.

A number of other research analysts have also issued reports on BDSI. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Tuesday, October 25th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 20th. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Piper Jaffray Cos. restated a “sell” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Finally, Janney Montgomery Scott upgraded shares of BioDelivery Sciences International from a “neutral” rating to a “buy” rating and increased their target price for the stock from $2.45 to $4.00 in a research report on Friday, September 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $6.43.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.94% during trading on Monday, reaching $1.65. 238,554 shares of the company’s stock traded hands. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $6.23. The firm has a 50 day moving average price of $2.13 and a 200-day moving average price of $2.37. The firm’s market cap is $89.29 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.04. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The company earned $3.60 million during the quarter, compared to analyst estimates of $3.58 million. During the same quarter last year, the company posted ($0.39) EPS. The firm’s quarterly revenue was up 200.0% on a year-over-year basis. On average, analysts forecast that BioDelivery Sciences International will post ($1.23) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was reported by Financial Market News and is owned by of Financial Market News. If you are viewing this story on another domain, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this story can be accessed at http://www.financial-market-news.com/biodelivery-sciences-international-inc-bdsi-pt-set-at-6-00-by-roth-capital/1208845/.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 100,000 shares of the firm’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $2.57, for a total value of $257,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 14,800 shares of the firm’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $2.44, for a total transaction of $36,112.00. Following the completion of the sale, the chief financial officer now owns 14,866 shares of the company’s stock, valued at $36,273.04. The disclosure for this sale can be found here. Insiders own 9.00% of the company’s stock.

Large investors have recently bought and sold shares of the company. KCG Holdings Inc. raised its position in BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock worth $106,000 after buying an additional 27,630 shares during the period. NEXT Financial Group Inc raised its position in BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock worth $135,000 after buying an additional 14,850 shares during the period. Alpine Partners VI LLC acquired a new position in BioDelivery Sciences International during the second quarter worth $147,000. Krilogy Financial LLC acquired a new position in BioDelivery Sciences International during the second quarter worth $164,000. Finally, Bank of New York Mellon Corp raised its position in BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock worth $170,000 after buying an additional 5,677 shares during the period. Institutional investors and hedge funds own 51.28% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.